Early studies on CTCs point towards the presence of PIK3CA hotspot mutations—along with the wild-type form of this gene—in MBC patients [27,28,29,30,31], regardless of the PIK3CA status in the primary tumor [29,30]. This evidence concerns the gene PIK3CA and neoplasm.